IQVIA Oncology Dynamics (Mexico)

Field Names
Records
Coordinating Country
Mexico

[IQVIA Oncology Dynamics (Mexico) is part of the IQVIA Global Oncology portfolio]

Region

All regions of Mexico

This profile describes the Mexican dataset from the IQVIA Oncology Dynamics portfolio. The full portfolio is a global database comprising patient records spanning 14 countries:
- Belgium
- Brazil
- Bulgaria
- China
- France
- Germany
- Italy
- Japan
- Mexico
- Romania
- Saudi Arabia
- South Korea
- Spain
- United Kingdom

Brief Database Description

IQVIA Oncology Dynamics (Mexico) part of the IQVIA Global Oncology portfolio, has complete patient oncology treatment information collected directly from physicians via a paper-based questionnaire. This profile describes the Mexican dataset from the IQVIA Oncology Dynamics portfolio since the year 2018. This database is not a statistical sample of the Mexican population; it is a descriptive cross-sectional database. There are a total of ~7,000 annual oncology drug-treated patients, and a total of >26,000 patients to date.

The full IQVIA Global Oncology portfolio is a global database comprising patient records spanning 14 countries: Belgium, Brazil, Bulgaria, China, France, Germany, Italy, Japan, Mexico, Romania, Saudi Arabia, South Korea, Spain, and the United Kingdom.  

Database Type
Cross-sectional Population Data
- Population Surveys - general (all diseases/or all drugs)

IQVIA Oncology Dynamics (Mexico) part of the IQVIA Global Oncology portfolio, has complete patient oncology treatment information collected directly from physicians via a paper-based questionnaire. This profile describes the Mexican dataset from the IQVIA Oncology Dynamics portfolio. This database is not a statistical sample of the Mexican population; it is a descriptive cross-sectional database. There are a total of ~7,000 annual oncology drug-treated patients, and a total of >26,000 patients to date.

The full IQVIA Global Oncology portfolio is a global database comprising patient records spanning 14 countries: Belgium, Brazil, Bulgaria, China, France, Germany, Italy, Japan, Mexico, Romania, Saudi Arabia, South Korea, Spain, and the United Kingdom.

Database Source
Medical Records

IQVIA Oncology Dynamics (Mexico) part of the IQVIA Global Oncology portfolio, has complete patient oncology treatment information collected directly from physicians via a paper-based questionnaire. This profile describes the Mexican dataset from the IQVIA Oncology Dynamics portfolio. This database is not a statistical sample of the Mexican population; it is a descriptive cross-sectional database. There are a total of ~7,000 annual oncology drug-treated patients, and a total of >26,000 patients to date.

Frequency of Data Collection
Ongoing
Frequency of Data Update
Quarterly

(Approximately 35 days after the end of a quarter)

Years Covered
2018 - Present

(Q1 2018 - Present)

Population Type
Outpatient/Non-Institutionalized

Inpatient

The database consists of drug-treated patients with one of the following indications:
- ALL
- CML
- CLL
- NHL
- Breast
- NSCLC
- Prostate
- Colorectal
- Bladder
- Kidney
- Multiple Myeloma
- Pancreas
- Ovarian Melanoma

Patient Type
Inpatient and Outpatient

The database consists of drug-treated patients with one of the following indications:
- ALL
- CML
- CLL
- NHL
- Breast
- NSCLC
- Prostate
- Colorectal
- Bladder
- Kidney
- Multiple Myeloma
- Pancreas
- Ovarian Melanoma

Date of Last Update
Ongoing

[The IQVIA Oncology Dynamics (Mexico) database is updated on an ongoing basis;
This profile was last updated for the B.R.I.D.G.E. TO DATA site on December 15, 2021.)

Field Names
Records
Database Population Size
<200,000

There are a total of >26,000 patients to date.

Active Population Size
<200,000

There are a total of ~7,000 annual oncology drug-treated patients.

Annual Change in Population
N/A

[Not applicable, as this is a cross-sectional survey with natural fallout collection. More specifically, annual sample targets for the database are not collected by indication and instead there are selection criteria for physician case reports to remove any bias (i.e., natural fall out).

Physicians are required to report the first consecutive cases during the reporting period. There is a limit to the number of cases that any one physician can report, regardless of indication.]

Sample Weights - Extrapolation Factors
No

The sample is not weighted in any way. It is meant to give a representative view of the treated prevalent cancer population.

Final Population Size
N/A

(Not applicable, as data collection is still ongoing)

Field Names
Records
Age of Patients at Data Collection
Yes

(YOB is collected)

Approximate Percentage of Participants <18 years and those >65 years

N/A

(Not applicable, as patients in the database are considered representative of the overall patient population)

Gender Data
Yes
Percentage of Males/Females

N/A

(Not applicable, as patients in the database are considered representative of the overall patient population)

Ethnicity / Race Data
No
Geographic Location

All areas of Mexico

Date of Birth Recorded
Yes

(Year)

Death Recorded
No
Availability of death certificate / autopsy information
N/A

(Not applicable)

Other Demographic Data
Yes

Information is collected on Risk Factors and Family History

Field Names
Records
Physician ID
No

All physicians have a unique ID number; however, this information is not available in the database.

Physician Specialty
Yes

There are ~80 cancer-treating physicians

Pharmacy ID
N/A

(Not applicable)

Field Names
Records
Diagnosis Data
Yes

Data collection covers all aspects of the patient’s chemotherapy treatment, from cancer diagnosis (including date of diagnosis and cancer type, respectable status, and disease progression), assignment therapy, date of therapy and details of the therapy administered, to full demographics that include stage of disease at diagnosis and at relapse. Regular reporting by a panel of physicians in France provides stability in the data.

Drug-treated patients are reported in the database:
1. Date of diagnosis and stage at diagnosis are captured. Therapy type at diagnosis is not necessarily captured unless the patient is newly diagnosed.
2. Patient's current treatment and one historic/previous treatment are captured. The dates of each reported therapy are also captured.
3. Full patient demographics are always captured.

Diagnoses Coded
ICD-10
Diagnoses: Date Parameters
2018 - Present

(Q1 2018 - Present)

Diagnoses: Maximum Number of Codes Allowed
1

(Only one Primary Cancer Diagnosis is listed)

Physical Examination Findings
Yes

Information is collected on family history and risk factors. However, no information is collected on height, weight, BMI, patient waist circumference, BP, or pulse rate.

Birth Defect Data
No
Cancer Data
Yes

The database consistes of drug-treated patients with one of the following indications:
- ALL
- CML
- CLL
- NHL
- Breast
- NSCLC
- Prostate
- Colorectal
- Bladder
- Kidney
- Multiple Myeloma
- Pancreas
- Ovarian Melanoma

Infectious Disease Data
No
Environmental Exposures
No
Behavioral Data Elements
Yes

Data are often collected on smoking status; however, there is no information regarding alcohol consumption.

Field Names
Records
Procedure Data
Yes

Information is available on:
- Regimen
- Route of admin
- Dose
- Quantity and frequency
- Current therapy
- Most recent previous line of therapy
- Current supportive therapy
- Maintenance therapy
- Therapy initiator
- Therapy context

Information is available on surgery, including stem cell transplant.

Procedures Coded
ICD-10
Number of Procedures Coded
Unlimited
Procedure Date Parameters
2018 - Present

(Q1 2018 - Present)

Laboratory Information
Yes

Information is available on:
- Biomarkers
- ECOG performance status
- Metastatic status
Additionally, data are captured on chromosomal abnormalities in CLL CML MM

Field Names
Records
Drug Data
Yes: Prescription only

Information is available on prescribed and administered drugs:
- Regimen
- Route of admin
- Dose
- Quantity and frequency
- Current therapy
- Most recent previous line of therapy
- Current supportive therapy
- Maintenance therapy
- Therapy initiator
- Therapy context

However, information on hospital drug treatment is limited.

Drug Date Parameters
2018 - Present

(Q1 2018 - Present)

Drug Regimen & Route
Yes

Information is available on Regimen, and Route of administration.

Drug Manufacturer
Yes
Drug Dosage
Yes

Posology or daily dose information is available

Drug Days Supply
Yes

Information is available on Quantity and Frequency

Drug Coding System: Maximum Number
Unlimited

However, this is limited by character length in data entry field.
NOTE: Some regimens have multiple drugs.

Drug Coding System: Primary
ATC-EPhMRA/IPMRG
Drug Coding System: Other
N/A

(Not applicable)

Drug Generic Name
Yes

Generic and brand name (where applicable) is requested.

Drug Additional Information
No
Field Names
Records
Biobank Type
N/A
Human Specimen
N/A
Blood Type
N/A
Biomarkers
N/A
Patient ID
N/A
Number of Samples
N/A
Frequency of Sample Collection
N/A
Pre-diagnostic Sample Collection
N/A
Post-treatment Sample Collection
N/A
Method of Sample Collection
N/A
Age at Sample Collection
N/A
Date of Sample Collection
N/A
Reason for Sample Collection
N/A
Method of Sample Storage
N/A
Length of Sample Storage
N/A
Pathology
N/A
DNA Isolation
N/A
RNA Isolation
N/A
Cell Culture
N/A
Genetic Testing
N/A
Access for Research: Specimens
N/A
Access for Research: Genetic Data
N/A
Access for Research: Epidemiologic Data
N/A
Quality Assurance Procedures
N/A
Family History
N/A
Medical History
N/A
Biobank Linkage
N/A
Field Names
Records
Type of Genetic Database
N/A
Source of Genetic Data
N/A
Specimen Genotyped
N/A
Tissue Form
N/A
Genetic Template
N/A
Gene-Drug Response
N/A
Gene-Disease Relationship
N/A
Gene-Health Outcome Relationship
N/A
Gene-Environment Response
N/A
Method of Imputing Genetic Data
N/A
Genetic Variant Identification
N/A
Genetic Data Level
N/A
Genotyping Method
N/A
Method of Genetic Variant Filtering
N/A
Haplotypes
N/A
Haplogroups
N/A
Variable Number of Tandem Repeats (VNTR)
N/A
Single Nucleotide Polymorphisms (SNPs)
N/A
Variant Type
N/A
Variant Class
N/A
Mutation Indicated
N/A
Position
N/A
Amino Acid Change
N/A
Genotype / Polymorphism
N/A
Allele Frequency
N/A
Linkage Disequilibrium (r²)
N/A
Noncarriers Indicated
N/A
Association Statistics
N/A
Genetic Relatedness Pairing
N/A
Data Sharing: Genetic Data
N/A
Access for Research
N/A
Genetic Data Linkage
N/A
Description of Genetic Data Linkage
N/A
Field Names
Records
Cost Data
No
Cost Denomination
N/A

(Not applicable)

Type of Cost Data
N/A

(Not applicable)

Surrogate Cost Data Link
No
Description of Surrogate Link
N/A

(Not applicable)

Field Names
Records
Data Validation Against Original Source
No

However, numerous quality checks are performed on the data collected to ensure accuracy

Access to Medical Records
No
Linkage to Other Databases
Yes

Linkage does exist

Brief Description of Linkage Capabilities

All Oncology Dynamics databases are linked; however, they are not linked to other IQVIA Health databases.

Field Names
Records
Database Contact Data

Email: RWDassets@iqvia.com

Website
https://www.iqvia.com/library/videos/oncology-dynamics
Alternate Contact

N/A

(Not applicable)

Source of Database Funding
Private

(IQVIA)

Sponsoring Government Agency
N/A

(Not applicable)

Sponsoring Pharmaceutical Manufacturer

N/A

(Not applicable)

Database Usage Restrictions
Private Access

This is a subscription database available to the pharmaceutical industry. Interested clients should contact email RWDassets@iqvia.com for more information re: access.

Charge for Database Usage
Yes

Please email database contact mentioned above re: costs related to any project or direct query

Data Media Format
Excel / CSV

Aggregated reports (excel, ppt, flatfiles, etc.)
Local BI software

Number of Publications Using Database
N/A

(Not applicable; there are no publications as this is a new database)

References of Studies Using/Describing Database

N/A

(Not applicable; there are no publications as this is a relatively new database)

Database Contact
Database Contact Data

Email: RWDassets@iqvia.com

Alternate Contact

N/A

References of Studies Using/Describing Database

N/A